Resumo (PT):
Novel anti-leishmanial target LmSir2 has few subtle
but prudent structural differences in ligand binding
and catalytic domain as compared to its human counterpart.
In silico screening and validation followed by
in vitro deacetylation and cell killing assays described
herein give a proof of concept for development of
strategies exploiting such minor differences for
screening libraries of small molecules to identify
selective inhibitors.
<br>
<br>
Key words: leishmaniasis, nicotinamide and virtual screening, Sir2
<br>
<a target="_blank" href="http://web.ebscohost.com/ehost/detail?vid=3&hid=106&sid=7436bf0e-ef17-48be-9c94-3f343d40468b%40sessionmgr109&bdata=JnNpdGU9ZWhvc3QtbGl2ZSZzY29wZT1zaXRl#db=a2h&AN=31573659#db=a2h&AN=31573659#db=a2h&AN=31573659"> Texto integral</a>
<br>
<br>
Abstract (EN):
Novel anti-leishmanial target LmSir2 has few subtle but prudent structural differences in ligand binding and catalytic domain as compared to its human counterpart. In silico screening and validation followed by in vitro deacetylation and cell killing assays described herein give a proof of concept for development of strategies exploiting such minor differences for screening libraries of small molecules to identify selective inhibitors.
Language:
English
Type (Professor's evaluation):
Scientific
No. of pages:
6